Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line.
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...
Eli Lilly also forecast annual profit largely above Wall Street estimates on Thursday, saying it expects to earn between $22.50 and $24.00 per share on an adjusted basis this year. Analysts were ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
Eli Lilly’s profit doubled in the fourth quarter as the Indianapolis-based drugmaker raked in revenue from diabetes and ...
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback